Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07131566Recruiting

Immune Response in Cervical Lymph Nodes of Patients With Head and Neck Cancer

Role: lead

NCT06061848Phase 2Recruiting

Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT

Role: lead

NCT04296474Phase 1Completed

Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass

Role: lead

NCT04210193Phase 2Completed

Is Intralymphatic Allergen Immunotherapy Effective and Safe?

Role: lead

All 4 trials loaded